Filing Details
- Accession Number:
- 0001140361-13-036133
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-09-17 14:44:49
- Reporting Period:
- 2013-09-13
- Filing Date:
- 2013-09-17
- Accepted Time:
- 2013-09-17 14:44:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1134545 | D Johnny Powers | One Idexx Drive Westbrook ME 04092 | Executive Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-09-13 | 16,128 | $34.37 | 22,117 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-09-13 | 13,128 | $96.59 | 8,989 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-09-13 | 5,492 | $0.00 | 5,492 | $34.37 |
| Common Stock | Incentive Stock Option (right to buy) | Disposition | 2013-09-13 | 10,636 | $0.00 | 10,636 | $34.37 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 2,372 | 2016-02-13 | No | 4 | M | Direct | |
| 2,909 | 2016-02-13 | No | 4 | M | Direct |
Footnotes
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $96.50 to $96.86, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock becomes exercisable as to 2,373 shares on 02/14/2010, 02/14/2011, 02/14/2012 and 02/14/2013, and the remaining 2,372 shares on 02/14/2014.
- Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date 02/14/2010 of the date of grant.
Billionaire Hedge Funds
